Overall, our results show that intranasal administration of CNS/CT-001 can reverse motor symptoms of PD, the loss of hind limb strength, reduce the amount of α-synuclein aggregates in the cortex and significantly reverse neurodegeneration of midbrain dopamine neurons in symptomatic PINK1-KO rats. Here, PINK1 is linked to Parkinson disease.